Genetic deletion of ASIC3 alters left ventricular remodeling and autonomic function after myocardial infarction in mice

TL;DR

Deleting ASIC3 in mice reduces harmful heart changes after a heart attack by affecting nerve signaling and blood pressure variability.

Contribution

This study reveals that ASIC3 deletion modulates cardiac remodeling and autonomic function after MI in mice.

Findings

ASIC3−/− mice showed reduced left ventricular dilation and improved cardiac function after MI.

ASIC3−/− mice exhibited altered autonomic responses, including lower baroreceptor sensitivity and higher systolic blood pressure variability.

ASIC3 may serve as a potential therapeutic target for heart failure.

Abstract

Cardiac afferent neurons have been shown to trigger overactivation of neurohormonal systems known to drive adverse cardiac remodeling following myocardial infarction (MI). Acid‐sensing ion channels (ASICs) that are highly expressed in cardiac sympathetic afferents sense ischemia‐induced myocardial acidosis. We hypothesized that genetic deletion of ASICs might abrogate disadvantageous remodeling after MI by disrupting afferent signaling pathways otherwise resulting in overactivation of neurohormonal responses. To test this, we induced MI in wild type (WT) and ASIC3−/− mice and assessed cardiac remodeling by serial echocardiography. We found that ASIC3−/− mice had less LV dilation relative to ischemic zone fraction, increased LV mass and wall thickness, and increased stroke volume compared to WT mice after MI. To investigate a potential role of the autonomic nervous system, we measured renal and splanchnic sympathetic nerve activity (SNA), heart rate and systolic blood pressure variability (sBPV), and hemodynamic responses to atropine and propranolol. Following MI, ASIC3−/− mice had lower baroreceptor‐renal SNA reflex sensitivity than WT mice, associated with elevated sBPV. Our data show that ASIC3 plays an important role in cardiac remodeling after MI potentially via modulation of baroreflex sensitivity and sBPV. ASIC3 may be further investigated as a potential therapeutic target in heart failure.

Figures